Open AccessIs carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?
Author(s) -
Jianbo Li,
Guojian Zhang,
Xuemei Wang,
Xiaofeng Li
Publication year - 2015
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon.15.11
Subject(s) - hypoxia (environmental) , tumor hypoxia , medicine , cancer research , monoclonal antibody , cancer cell , cancer , pathology , antibody , immunology , chemistry , radiation therapy , organic chemistry , oxygen
The presence of hypoxia is a general feature of most solid malignancies, and hypoxia is considered as one of major factors for anticancer therapy failure. Carbonic anhydrase IX (CAIX) has been reported to be an endogenous hypoxia marker, CAIX monoclonal antibodies, their segments and inhibitors are developed for CAIX imaging. However, growing evidence indicates that CAIX expression under hypoxia condition may be cancer cell lines or cancer-type dependent. Here we review the current literature on CAIX and discuss the advantage and limitation of CAIX as a target for tumor hypoxia imaging. Accordingly, CAIX would be unreliable as a universal target for cancer and tumor hypoxia visualization.